The microbiome and ovarian cancer: insights, implications, and therapeutic opportunities

Abstract

Ovarian cancer is the leading cause of gynecologic cancer death in the United States. Most ovarian cancer patients are diagnosed with advanced-stage disease, which poses a challenge for early detection and effective treatment. At present, cytoreductive surgery and platinum-based chemotherapy are foundational for patients with newly diagnosed ovarian cancer, but unfortunately, most patients will recur and die of their disease. Therefore, there is a significant need to seek innovative, novel approaches for early detection and to overcome chemoresistance for ovarian cancer patients. The microbiome, comprising diverse microbial communities inhabiting various body sites, is vital in maintaining human health. Changes to the diversity and composition of the microbial communities impact the microbiota-host relationship and are linked to diseases, including cancer. The microbiome contributes to carcinogenesis through various mechanisms, including altered host immune response, modulation of DNA repair, upregulation of pro-inflammatory pathways, altered gene expression, and dysregulated estrogen metabolism. Translational and clinical studies have demonstrated that specific microbes contribute to ovarian cancer development and impact chemotherapy’s efficacy. The microbiome is malleable and can be altered through different approaches, including diet, exercise, medications, and fecal microbiota transplantation. This review provides an overview of the current literature regarding ovarian cancer and the microbiome of female reproductive and gastrointestinal tracts, focusing on mechanisms of carcinogenesis and options for modulating the microbiota for cancer prevention and treatment. Advancing our understanding of the complex relationship between the microbiome and ovarian cancer may provide a novel approach for prevention and therapeutic modulation in the future.

Keywords

Ovarian cancer / gynecological cancer / microbiota / microbiome / platinum-based chemotherapy / dysbiosis

References

[1] Lheureux S,Oza AM.Epithelial ovarian cancer: evolution of management in the era of precision medicine.CA Cancer J Clin2019;69:280-304

[2] Siegel RL,Fuchs HE.Cancer statistics, 2022.CA Cancer J Clin2022;72:7-33

[3] Boehm KM,Ellenson L.MSK MIND ConsortiumMultimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer.Nat Cancer2022;3:723-33 PMCID:PMC9239907

[4] Cancer of the ovary - cancer stat facts. SEER. Available from: https://seer.cancer.gov/statfacts/html/ovary.html. [Last accessed on 15 Nov 2023].

[5] Elsherif S,Viswanathan C,Bhosale P.Low-grade epithelial ovarian cancer: what a radiologist should know.Br J Radiol2019;92:20180571 PMCID:PMC6541194

[6] Tossetta G.Metformin improves ovarian cancer sensitivity to paclitaxel and platinum-based drugs: a review of in vitro findings.Int J Mol Sci2022;23:12893 PMCID:PMC9654053

[7] Hollis RL.Genetic and molecular changes in ovarian cancer.Cancer Biol Med2016;13:236-47 PMCID:PMC4944549

[8] Elkafas H,Al-Hendy A.Gut and genital tract microbiomes: dysbiosis and link to gynecological disorders.Front Cell Infect Microbiol2022;12:1059825 PMCID:PMC9800796

[9] Łaniewski P,Herbst-Kralovetz MM.The microbiome and gynaecological cancer development, prevention and therapy.Nat Rev Urol2020;17:232-50 PMCID:PMC9977514

[10] Mirza MR,González-Martín A.The forefront of ovarian cancer therapy: update on PARP inhibitors.Ann Oncol2020;31:1148-59

[11] Haunschild CE.Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.Future Oncol2020;16:225-46 PMCID:PMC7036749

[12] Pujade-Lauraine E,Pignata S.Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives.J Clin Oncol2019;37:2437-48

[13] Banerjee S,Richardson DL.Targeting NaPi2b in ovarian cancer.Cancer Treat Rev2023;112:102489

[14] Garcia J,Sandler AB.Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook.Cancer Treat Rev2020;86:102017

[15] Borella F,Cosma S.Gut microbiota and gynecological cancers: a summary of pathogenetic mechanisms and future directions.ACS Infect Dis2021;7:987-1009

[16] Armstrong DK,Backes FJ.NCCN Guidelines® insights: ovarian cancer, version 3. 2022.J Natl Compr Canc Netw2022;20:972-80

[17] Coleridge SL,Lyons TJ,Kehoe S.Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.Cochrane Database Syst Rev2019;2019:CD005343 PMCID:PMC6822157

[18] Yang L,Li YY,Liu XX.Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (review).Oncol Rep2022;47:82 PMCID:PMC8908330

[19] Richardson DL,O'Malley DM.Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review.JAMA Oncol2023;9:851-9

[20] Zhao LY,Yu G.Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications.Signal Transduct Target Ther2023;8:201 PMCID:PMC10183032

[21] Adak A.An insight into gut microbiota and its functionalities.Cell Mol Life Sci2019;76:473-93

[22] Uemura N,Yamamoto S.Helicobacter pylori infection and the development of gastric cancer.N Engl J Med2001;345:784-9

[23] Zampino R,Cirillo G.Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. Ann Hepatol 2015;14:75-82.

[24] Kostic AD,Pedamallu CS.Genomic analysis identifies association of fusobacterium with colorectal carcinoma.Genome Res2012;22:292-8 PMCID:PMC3266036

[25] Sadrekarimi H,Bakhshesh M.Emerging role of human microbiome in cancer development and response to therapy: special focus on intestinal microflora.J Transl Med2022;20:301 PMCID:PMC9258144

[26] Lin HW,Lin SY.Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study.Lancet Oncol2011;12:900-4

[27] Idahl A,Jurstrand M.Chlamydia trachomatis and mycoplasma genitalium plasma antibodies in relation to epithelial ovarian tumors.Infect Dis Obstet Gynecol2011;2011:824627 PMCID:PMC3147007

[28] Idahl A,González Maldonado S.Serologic markers of chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: results from the EPIC cohort.Int J Cancer2020;147:2042-52

[29] Rasmussen CB,Albieri V,Kjaer SK.Increased risk of borderline ovarian tumors in women with a history of pelvic inflammatory disease: a nationwide population-based cohort study.Gynecol Oncol2016;143:346-51

[30] Fortner RT,Bender N.Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies.Br J Cancer2019;120:855-60 PMCID:PMC6474309

[31] Shanmughapriya S,Vinodhini K,Vasanthi N.Viral and bacterial aetiologies of epithelial ovarian cancer.Eur J Clin Microbiol Infect Dis2012;31:2311-7

[32] Round JL,Li J.The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota.Science2011;332:974-7 PMCID:PMC3164325

[33] Rutkowski MR,Svoronos N.Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation.Cancer Cell2015;27:27-40 PMCID:PMC4293269

[34] Fang Y,Zhao Q.The association between gut microbiota, toll-like receptors, and colorectal cancer.Clin Med Insights Oncol2022;16:11795549221130549 PMCID:PMC9634190

[35] Le Noci V, Bernardo G, Bianchi F, Tagliabue E, Sommariva M, Sfondrini L. Toll like receptors as sensors of the tumor microbial dysbiosis: implications in cancer progression.Front Cell Dev Biol2021;9:732192 PMCID:PMC8485072

[36] Couturier-Maillard A,Rehman A.NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer.J Clin Invest2013;123:700-11 PMCID:PMC3561825

[37] Zhou B,Huang J.The biodiversity composition of microbiome in ovarian carcinoma patients.Sci Rep2019;9:1691 PMCID:PMC6368644

[38] Browning L,Horvath EB,Jorcyk CL.IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis.Cancer Manag Res2018;10:6685-93 PMCID:PMC6287645

[39] Savant SS,O'Hagan HM.The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer.Cancers2018;10:251 PMCID:PMC6116184

[40] Ghanavati R,Mohammadi F.Lactobacillus species inhibitory effect on colorectal cancer progression through modulating the Wnt/β-catenin signaling pathway.Mol Cell Biochem2020;470:1-13

[41] Chung L,Geis AL.Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells.Cell Host Microbe2018;23:203-14.e5 PMCID:PMC5954996

[42] Suriano F,Sergi D.Diet, microbiota, and the mucus layer: the guardians of our health.Front Immunol2022;13:953196 PMCID:PMC9513540

[43] Lupi LA,Silveira HS.The role of Toll-like receptor 4 signaling pathway in ovarian, cervical, and endometrial cancers.Life Sci2020;247:117435

[44] Kelly MG,Chen R.TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.Cancer Res2006;66:3859-68

[45] Szajnik M,Czystowska M.TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.Oncogene2009;28:4353-63 PMCID:PMC2794996

[46] Zandi Z,Poursani EM.TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition.Eur J Pharmacol2019;853:256-63

[47] Plottel CS.Microbiome and malignancy.Cell Host Microbe2011;10:324-35 PMCID:PMC3264051

[48] Peters BA,Qi Q.Menopause is associated with an altered gut microbiome and estrobolome, with implications for adverse cardiometabolic risk in the hispanic community health study/study of latinos.mSystems2022;7:e0027322 PMCID:PMC9239235

[49] Cheng H,Cui L.Opportunities and challenges of the human microbiome in ovarian cancer.Front Oncol2020;10:163 PMCID:PMC7040031

[50] Brewster WR,Ko EM,Nicole McCoy A.An evaluation of the microbiota of the upper reproductive tract of women with and without epithelial ovarian cancer.Gynecol Oncol Rep2022;42:101017 PMCID:PMC9218206

[51] Miao R,Groesch K.Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer.PLoS One2020;15:e0227707 PMCID:PMC6952086

[52] Banerjee S,Wei Z.The ovarian cancer oncobiome.Oncotarget2017;8:36225-45 PMCID:PMC5482651

[53] Asangba AE,Goergen KM.Diagnostic and prognostic potential of the microbiome in ovarian cancer treatment response.Sci Rep2023;13:730 PMCID:PMC9839674

[54] Nené NR,Leimbach A.Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study.Lancet Oncol2019;20:1171-82

[55] Chen L,Wang Y.Altering the microbiome inhibits tumorigenesis in a mouse model of oviductal high-grade serous carcinoma.Cancer Res2021;81:3309-18 PMCID:PMC8260454

[56] Jacobson D,Gunderson C.Shifts in gut and vaginal microbiomes are associated with cancer recurrence time in women with ovarian cancer.PeerJ2021;9:e11574 PMCID:PMC8214851

[57] Wang Z,Hu D.Akkermansia supplementation reverses the tumor-promoting effect of the fecal microbiota transplantation in ovarian cancer.Cell Rep2022;41:111890

[58] Pflug N,Vehreschild JJ.Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota.Oncoimmunology2016;5:e1150399 PMCID:PMC4938364

[59] Chambers LM,Bharti R.Disruption of the gut microbiota confers cisplatin resistance in epithelial ovarian cancer.Cancer Res2022;82:4654-69 PMCID:PMC9772178

[60] Chambers LM,Yao M.Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.Gynecol Oncol2020;159:699-705

[61] Chambers LM,Rose PG,Yao M.Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer.Gynecol Oncol2021;161:211-20

[62] Routy B,Derosa L.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science2018;359:91-7

[63] Viaud S,Mignot G.The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.Science2013;342:971-6 PMCID:PMC4048947

[64] Pinato DJ,Ottaviani D.Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer.JAMA Oncol2019;5:1774-8 PMCID:PMC6743060

[65] Gopalakrishnan V,Nezi L.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Science2018;359:97-103

[66] Abdel-rahman O,Walker J.Outcomes of metastatic colorectal cancer patients in relationship to prior and concurrent antibiotics use; individual patient data analysis of three clinical trials.Clin Transl Oncol2020;22:1651-6

[67] D’amico F,Rampelli S.Gut microbiota dynamics during chemotherapy in epithelial ovarian cancer patients are related to therapeutic outcome.Cancers2021;13:3999 PMCID:PMC8393652

[68] Spakowicz D,Muniak M.Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications.BMC Cancer2020;20:383 PMCID:PMC7201618

[69] Iida N,Stewart CA.Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.Science2013;342:967-70 PMCID:PMC6709532

[70] Yin B,Yuan F,Lu P.Research progress on the effect of gut and tumor microbiota on antitumor efficacy and adverse effects of chemotherapy drugs.Front Microbiol2022;13:899111 PMCID:PMC9538901

[71] Ma W,Xia W,Yu C.Gut microbiota shapes the efficiency of cancer therapy.Front Microbiol2019;10:1050 PMCID:PMC6604670

[72] Rea D,Palma G.Microbiota effects on cancer: from risks to therapies.Oncotarget2018;9:17915-27 PMCID:PMC5915165

[73] Wilkinson EM,Herbst-Kralovetz MM.Microbiota-drug interactions: impact on metabolism and efficacy of therapeutics.Maturitas2018;112:53-63

[74] Lin C,Zhang J.Role of gut microbiota in the development and treatment of colorectal cancer.Digestion2019;100:72-8

[75] Chambers LM,Vargas R.The microbiome and gynecologic cancer: current evidence and future opportunities.Curr Oncol Rep2021;23:92

[76] Mahdi H,Slomovitz BM.Immunotherapy in endometrial cancer.Int J Gynecol Cancer2023;33:351-57

[77] Disis ML,Bajpai J.Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.J Immunother Cancer2023;11:e006624 PMCID:PMC10277149

[78] Baek MH,Ha HI.Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer: a meta-analysis.J Clin Oncol2022;40:1659-70

[79] Clair KH,Zell JA.Surgical management of gynecologic cancers.Surg Oncol Clin N Am2021;30:69-88

[80] Chang SJ,Chang J.Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.Gynecol Oncol2013;130:493-98

[81] Tong J,Fan Y.Changes of intestinal microbiota in ovarian cancer patients treated with surgery and chemotherapy.Cancer Manag Res2020;12:8125-35 PMCID:PMC7494227

[82] Alam Z,Effat K.The potential role of prebiotics, probiotics, and synbiotics in adjuvant cancer therapy especially colorectal cancer.J Food Biochem2022;46:e14302

[83] Huang F,Chen W.Postoperative probiotics administration attenuates gastrointestinal complications and gut microbiota dysbiosis caused by chemotherapy in colorectal cancer patients.Nutrients2023;15:356 PMCID:PMC9861237

[84] Pitsillides L,Tekkis P.The effect of perioperative administration of probiotics on colorectal cancer surgery outcomes.Nutrients2021;13:1451 PMCID:PMC8146873

[85] Zhang LM,White MG.Combined mechanical and oral antibiotic bowel preparation is associated with prolonged recurrence-free survival following surgery for colorectal cancer.J Surg Oncol2021;124:1106-14 PMCID:PMC8610428

[86] Spencer CN,Gopalakrishnan V.Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.Science2021;374:1632-40

[87] David LA,Carmody RN.Diet rapidly and reproducibly alters the human gut microbiome.Nature2014;505:559-63 PMCID:PMC3957428

[88] Dizman N,Bergerot PG.Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma.Cancer Med2021;10:79-86 PMCID:PMC7826461

[89] Baruch EN,Ben-Betzalel G.Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.Science2021;371:602-9

[90] Ahrén IL,Steineck G,Jeppsson B.Decreasing the adverse effects in pelvic radiation therapy: a randomized controlled trial evaluating the use of probiotics.Adv Radiat Oncol2023;8:101089 PMCID:PMC9723296

[91] Davar D,McCulloch JA.Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.Science2021;371:595-602 PMCID:PMC8097968

[92] Garczyk A,Drogowski K.Influence of probiotics in prevention and treatment of patients who undergo chemotherapy or/and radiotherapy and suffer from mucositis, diarrhoea, constipation, nausea and vomiting.J Clin Med2022;11:3412 PMCID:PMC9224909

[93] Abdolalipour E,Salehzadeh A.Evaluation of the antitumor immune responses of probiotic bifidobacterium bifidum in human papillomavirus-induced tumor model.Microb Pathog2020;145:104207

[94] del Giglio A, Atui FC. Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: a case report.World J Clin Cases2023;11:5830-4 PMCID:PMC10505991

[95] Mahdy MS,Dishisha T.Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate irinotecan-associated toxicity.BMC Microbiol2023;23:53 PMCID:PMC9979425

[96] Gu J,Riedl KM,Clinton SK.Characterization of black raspberry functional food products for cancer prevention human clinical trials.J Agric Food Chem2014;62:3997-4006 PMCID:PMC4133319

[97] Xu M,Zhu J.Evaluating metabolic response to light exposure in lactobacillus species via targeted metabolic profiling.J Microbiol Methods2017;133:14-9

[98] Chen J,Vitetta L.Effects of intestinal microbial-elaborated butyrate on oncogenic signaling pathways.Nutrients2019;11:1026 PMCID:PMC6566851

[99] Donohoe DR,Collins LB.A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner.Cancer Discov2014;4:1387-97

[100] Arpaia N,Fan X.Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation.Nature2013;504:451-5 PMCID:PMC3869884

[101] Beyaz S,Mou H.Dietary suppression of MHC class II expression in intestinal epithelial cells enhances intestinal tumorigenesis.Cell Stem Cell2021;28:1922-35.e5 PMCID:PMC8650761

[102] Morton M,Sciuva J.Malnutrition, sarcopenia, and cancer cachexia in gynecologic cancer.Gynecol Oncol2023;175:142-55

[103] Polen-de C,Weaver AL.Quality is more important than quantity: pre-operative sarcopenia is associated with poor survival in advanced ovarian cancer.Int J Gynecol Cancer2022;32:1289-96

[104] Seebacher V,Nobbenhuis M.The impact of nutritional risk factors and sarcopenia on survival in patients treated with pelvic exenteration for recurrent gynaecological malignancy: a retrospective cohort study.Arch Gynecol Obstet2022;305:1343-52 PMCID:PMC9013326

[105] Rinninella E,Cintoni M.Skeletal muscle mass as a prognostic indicator of outcomes in ovarian cancer: a systematic review and meta-analysis.Int J Gynecol Cancer2020;30:654-63

[106] Bekos C,Gensthaler L.The pretreatment controlling nutritional status score in ovarian cancer: influence on prognosis, surgical outcome, and postoperative complication rate.Geburtshilfe Frauenheilkd2022;82:59-67 PMCID:PMC8747899

[107] Wang Y,Lane NE.Population-based metagenomics analysis reveals altered gut microbiome in sarcopenia: data from the Xiangya Sarcopenia Study.J Cachexia Sarcopenia Muscle2022;13:2340-51 PMCID:PMC9530518

[108] Jiang Y,Zhang D,Wang X.The altered tight junctions: an important gateway of bacterial translocation in cachexia patients with advanced gastric cancer.J Interferon Cytokine Res2014;34:518-25 PMCID:PMC4080858

[109] About the SEER registries. SEER. Available from: https://seer.cancer.gov/registries/index.html. [Last accessed on 15 Nov 2023].